Channel Blockers

  • Sergio Canavero
  • Vincenzo Bonicalzi


The first recorded treatment of neuropathic pain with a sodium (Na+) channel blocker is probably Sigmund Freud’s treatment of Ernst von Fleischl’s trigeminal neuralgia with cocaine injections. Deisenhammer et al. [1] published the first Medline-indexed paper detailing the use of a Na+ channel blocker (carbamazepine) for CP (Tables 13.1, 13.2, 13.3, 13.4, 13.5, 13.6, 13.7, 13.8, 13.9, 13.10, 13.11, 13.12, 13.13, 13.14, 13.15, and 13.16).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Deisenhammer E, Scherrer H, Schnopfhagen O. [Carbamazepine in thalamic hyperpathia]. [Article in German]. Wien Med Wochenschr. 1969;119(25):475–6.PubMedGoogle Scholar
  2. 2.
    Attal N, Gaudé V, Brasseur L, Dupuy M, Guirimand F, Parker F, Bouhassira D. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology. 2000;54(3):564–74.CrossRefPubMedGoogle Scholar
  3. 3.
    Kvarnström A, Karlsten R, Quiding H, Gordh T. The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. Acta Anaesthesiol Scand. 2004;48(4):498–506.CrossRefPubMedGoogle Scholar
  4. 4.
    Finnerup NB, Biering-Sørensen F, Johannesen IL, Terkelsen AJ, Juhl GI, Kristensen AD, Sindrup SH, Bach FW, Jensen TS. Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial. Anesthesiology. 2005;102(5):1023–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Sang C, Jenkins K, Wang K, Sarin A, Coccoli S. Fosphenytoin relieves central neuropathic pain following spinal cord injury. J Pain. 2006;7(Suppl 1):2 A312/692.Google Scholar
  6. 6.
    Mailis-Gagnon A, Yegneswaran B, Bharatwal B, Krassioukov AV. Effects of intravenous sodium amobarbital vs. lidocaine on pain and sensory abnormalities in patients with spinal cord injury. J Spinal Cord Med. 2009;32(1):49–53.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Leijon G, Boivie J. Central post-stroke pain—a controlled trial of amitriptyline and carbamazepine. Pain. 1989;36(1):27–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Salinas FA, Lugo LH, Garcıa HI. Efficacy of early treatment with carbamazepine in prevention of neuropathic pain in patients with spinal cord injury. Am J Phys Med Rehabil. 2012;91:1020–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Kalita J, Chandra S, Misra UK. Pregabalin and lamotrigine in central poststroke pain: A pilot study. Neurol India 2017;65(3): 506–511.CrossRefGoogle Scholar
  10. 10.
    Chiou-Tan FY, Tuel SM, Johnson JC, Priebe MM, Hirsh DD, Strayer JR. Effect of mexiletine on spinal cord injury dysesthetic pain. Am J Phys Med Rehabil. 1996;75(2):84–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology. 2001;56(2):184–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96(3):375–83.CrossRefPubMedGoogle Scholar
  13. 13.
    Breuer B, Pappagallo M, Knotkova H, Guleyupoglu N, Wallenstein S, Portenoy RK. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther. 2007;29(9):2022–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Silver M, Blum D, Grainger J, Hammer AE, Quessy S. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manag. 2007;34(4):446–54.CrossRefGoogle Scholar
  15. 15.
    Agarwal N, Joshi M. Effectiveness of amitriptyline and lamotrigine in traumatic spinal cord injury-induced neuropathic pain: a randomized longitudinal comparative study. Spinal Cord. 2017;55(2):126–30 (in press).Google Scholar
  16. 16.
    Harden R, Houle T, Tyburski M, Tivedi K, Khan A, DiMaio A, Gagnon C. Levetiracetam in the management of neuropathic pain conditions: a double blind, randomized, crossover, placebo controlled pilot study using time series and hierarchical analysis. J Pain. 2006;7(4 Suppl):S34 (A727).Google Scholar
  17. 17.
    Finnerup NB, Grydehøj J, Bing J, Johannesen IL, Biering-Sørensen F, Sindrup SH, Jensen TS. Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord. 2009;47(12):861–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Rossi S, Mataluni G, Codecà C, Fiore S, Buttari F, Musella A, Castelli M, Bernardi G, Centonze D. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol. 2009;16(3):360–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Falah M, Madsen C, Holbech JV, Sindrup SH. A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. Eur J Pain. 2012;16(6):860–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Jungehulsing GJ, Israel H, Safar N, Taskin B, Nolte CH, Brunecker P, Wernecke KD, Villringer A. Levetiracetam in patients with central neuropathic post-stroke pain—a randomized, double-blind, placebo-controlled trial. Eur J Neurol. 2013;20(2):331–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Harden R, Brenman E, Saltz S, Houle T. Topiramate in the management of spinal cord injury pain: a double blind, randomised, placebo-controlled pilot study. Progr Pain Res Manage. 2002;23:393–407.Google Scholar
  22. 22.
    Boas RA, Covino BG, Shahnarian A. Analgesic responses to i.v. lignocaine. Br J Anaesth. 1982;54(5):501–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Backonja M, Gombar KA. Response of central pain syndromes to intravenous lidocaine. J Pain Symptom Manag. 1992;7(3):172–8.CrossRefGoogle Scholar
  24. 24.
    Edmondson EA, Simpson RK Jr, Stubler DK, Beric A. Systemic lidocaine therapy for poststroke pain. South Med J. 1993;86(10):1093–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Galer BS, Miller KV, Rowbotham MC. Response to intravenous lidocaine infusion differs based on clinical diagnosis and site of nervous system injury. Neurology. 1993;43(6):1233–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Nagaro T, Shimizu C, Inoue H, Fujitani T, Adachi N, Amakawa K, Kimura S, Arai T, Watanabe T, Oka S. The efficacy of intravenous lidocaine on various types of neuropathic pain. Masui. 1995;44(6):862–7.PubMedGoogle Scholar
  27. 27.
    Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci. 1999;162(2):162–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Trentin L, Visentin M. La predittività del test con lidocaina nel trattamento del dolore neuropatico. Minerva Anestesiol. 2000;66(3):157–61.PubMedGoogle Scholar
  29. 29.
    Cahana A, Carota A, Montadon ML, Annoni JM. The long-term effect of repeated intravenous lidocaine on central pain and possible correlation in positron emission tomography measurements. Anesth Analg. 2004;98(6):1581–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Bharadwaj P, Danilychev M. Central post-stroke syndrome treated with parenteral lidocaine. J Pain Symptom Manag. 2006;32(5):400–1.CrossRefGoogle Scholar
  31. 31.
    Wasner G, Naleschinski D, Baron R. A role for peripheral afferents in the pathophysiology and treatment of at-level neuropathic pain in spinal cord injury? A case report. Pain. 2007;131(1–2):219–25.CrossRefPubMedGoogle Scholar
  32. 32.
    Hans GH, Robert DN, Van Maldeghem KN. Treatment of an acute severe central neuropathic pain syndrome by topical application of lidocaine 5% patch: a case report. Spinal Cord. 2008;46(4):311–3.CrossRefPubMedGoogle Scholar
  33. 33.
    Kern KU, Kohl M, Kiefer RT. Lidocain-Pflaster zur Therapie neuropatischer und nichtneuropatischer Schmerzen. Klinische Fallstudie an 87 patienten. Nervenarzt. 2010;81(12):1490–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Freo U, Ambrosio F, Furnari M, Ori C. Lidocaine 5% medicated plaster for spinal neuropathic pain. J Pain Palliat Care Pharmacother. 2016;30(2):111–3.CrossRefPubMedGoogle Scholar
  35. 35.
    Awerbuch GI, Sandyk R. Mexiletine for thalamic pain syndrome. Int J Neurosci. 1990;55(2–4):129–33.CrossRefPubMedGoogle Scholar
  36. 36.
    Bowsher D. La douleur neurogene. Doul Analg. 1994;7(2):65–9.CrossRefGoogle Scholar
  37. 37.
    Canavero S, Bonicalzi V. Mexiletine–gabapentin for central pain: an efficacy and long-term study. In: 11th world congress on pain, book of abstracts. Seattle: IASP Press; 2005. P-218 (A596 P-202).Google Scholar
  38. 38.
    Cardenas DD, Jensen MP. Treatments for chronic pain in persons with spinal cord injury: a survey study. J Spinal Cord Med. 2006;29(2):109–17.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Carroll IR, Kaplan KM, Mackey SC. Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success. J Pain Symptom Manag. 2008;35(3):321–6.CrossRefGoogle Scholar
  40. 40.
    Albert ML. Treatment of pain in multiple sclerosis—preliminary report. N Engl J Med. 1969;280(25):1395.CrossRefPubMedGoogle Scholar
  41. 41.
    Espir ML, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry. 1970;33(4):528–31.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Gibson JC, White LE Jr. Denervation hyperpathia: a convulsive syndrome of the spinal cord responsive to carbamazepine therapy. J Neurosurg. 1971;35(3):287–90.CrossRefPubMedGoogle Scholar
  43. 43.
    Ekbom K. Carbamazepine in the treatment of tabetic lightning pains. Arch Neurol. 1972;26(4):374–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Giménez-Roldán S, Martín M. Tabetic lightning pains: high-dosage intravenous penicillin versus carbamazepine therapy. Eur Neurol. 1981;20(5):424–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Sandford PR, Lindblom LB, Haddox JD. Amitriptyline and carbamazepine in the treatment of dysesthesia pain in spinal cord injury. Arch Phys Medic Rehab. 1992;73(3):300–1.Google Scholar
  46. 46.
    Jenkins KR, Kaplan SE, Leahy L, Sang CN. Oxcarbazepine in central neuropathic pain with allodynia following spinal cord injury. Am Pain Soc Abstracts. 2002;3(2 Suppl):10 (A637).Google Scholar
  47. 47.
    Montes C, Magnin M, Maarrawi J, Frot M, Convers P, Mauguière F, Garcia-Larrea L. Thalamic thermo-algesic transmission: ventral posterior (VP) complex versus VMpo in the light of a thalamic infarct with central pain. Pain. 2005;113(1–2):223–32.CrossRefPubMedGoogle Scholar
  48. 48.
    Solaro C, Restivo D, Mancardi GL, Tanganelli P. Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. Neurol Sci. 2007;28(3):156–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Min K, Oh Y, Lee SH, Ryu JS. Symptom-based treatment of neuropathic pain in spinal cord-injured patients: a randomized crossover clinical trial. Am J Phys Med Rehabil. 2016;95(5):330–8.PubMedGoogle Scholar
  50. 50.
    Fine W. Post-hemiplegic epilepsy in the elderly. Br Med J. 1967;1(5534):199–201.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Cantor FK. Phenytoin treatment of thalamic pain. Br Med J. 1972;4(5840):590.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Mladinich EK. Letter: Diphenylhydantoin in the Wallenberg syndrome. JAMA. 1974;230(3):372–3.CrossRefPubMedGoogle Scholar
  53. 53.
    Agnew DC, Goldberg VD. A brief trial of phenytoin therapy for thalamic pain. Bull Los Angel Neurol Soc. 1976;41(1):9–12.Google Scholar
  54. 54.
    Canavero S, Bonicalzi V. Lamotrigine control of central pain. Pain. 1996;68(1):179–81.CrossRefPubMedGoogle Scholar
  55. 55.
    Carrieri PB, Provitera VV, Lavorgna L, Bruno R. Response of thalamic pain syndrome to lamotrigine. Eur J Neurol. 1998;5(6):625–6.CrossRefPubMedGoogle Scholar
  56. 56.
    McCleane G. Lamotrigine can reduce neurogenic pain associated with multiple sclerosis. Clin J Pain. 1998;14(3):269–70.CrossRefPubMedGoogle Scholar
  57. 57.
    McCleane GJ. A prospective audit of the use of lamotrigine in 300 chronic pain patients. Pain Clin. 1998;11:97–102.Google Scholar
  58. 58.
    Cianchetti C, Zuddas A, Randazzo AP, Perra L, Marrosu MG. Lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations. Neurology. 1999;53(2):433.CrossRefPubMedGoogle Scholar
  59. 59.
    Van Bastelaere M, De Laat M. Lamotrigine: a morphine-sparing drug for central pain. In: 9th world congress on pain, book of abstracts. Seattle: IASP Press; 1999. p. A211–P65.Google Scholar
  60. 60.
    Petramfar P, Nikseresht AR, Yaghoubi E. The effects of lamotrigine on pain, sleep, and mood in refractory form of central post-stroke pain syndrome. Iran J Med Sci. 2010;35:299–303.Google Scholar
  61. 61.
    D’Aleo G, Sessa E, Di Bella P, Rifici C, Restivo DA, Bramanti P. Topiramate modulation of R3 nociceptive reflex in multiple sclerosis patients suffering paroxysmal symptoms. J Neurol. 2001;248(11):996–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Canavero S, Bonicalzi V, Paolotti R. Lack of effect of topiramate for central pain. Neurology. 2002;58(5):831–2.CrossRefPubMedGoogle Scholar
  63. 63.
    Calabrò RS, Marra A, Quattrini F, Gervasi G, Levita A, Bramanti P. Central neuropathic pain: an unusual case of painful ejaculation responding to topiramate. J Sex Med. 2012;9(12):3274–8.CrossRefPubMedGoogle Scholar
  64. 64.
    Siniscalchi A, Gallelli L, De Sarro G. Effects of topiramate on dysaesthetic pain in a patient with multiple sclerosis. Clin Drug Investig. 2013;33(2):151–4.CrossRefPubMedGoogle Scholar
  65. 65.
    Mori F, Codecà C, Kusayanagi H, Monteleone F, Buttari F, Fiore S, Bernardi G, Koch G, Centonze D. Effects of anodal transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis. J Pain. 2010;11(5):436–42.CrossRefPubMedGoogle Scholar
  66. 66.
    Takahashi Y, Hashimoto K, Tsuji S. Successful use of zonisamide for central poststroke pain. J Pain. 2004;5(3):192–4.CrossRefPubMedGoogle Scholar
  67. 67.
    García-Escrivá A, López-Hernández N, Gil-Cortés C. Tratamiento del dolor neuropático con lacosamida. Rev Neurol. 2012;54:167–72.PubMedGoogle Scholar
  68. 68.
    Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013;14(1):49–62.CrossRefPubMedGoogle Scholar
  69. 69.
    Dib-Hajj SD, Black JA, Waxman SG. NaV1.9: a sodium channel linked to human pain. Nat Rev Neurosci. 2015;16(9):511–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Han C, Huang J, Waxman SG. Sodium channel Nav1.8: emerging links to human disease. Neurology. 2016;86(5):473–83.CrossRefPubMedGoogle Scholar
  71. 71.
    Tanaka BS, Zhao P, Dib-Hajj FB, Morisset V, Tate S, Waxman SG, Dib-Hajj SD. A gain-of-function mutation in Nav1.6 in a case of trigeminal neuralgia. Mol Med. 2016;22:338–48.Google Scholar
  72. 72.
    Gould HJ III, Diamond I. Ranolazine: a potential treatment for refractory neuropathic pain. Ranolazine: a potential treatment for refractory neuropathic pain. J Neurol Sci. 2016;369:310–1.CrossRefPubMedGoogle Scholar
  73. 73.
    Hutson P, Backonja M, Knurr H. Intravenous lidocaine for neuropathic pain: a retrospective analysis of tolerability and efficacy. Pain Med. 2015;16(3):531–6.CrossRefPubMedGoogle Scholar
  74. 74.
    Mooney JJ, Pagel PS, Kundu A. Safety, tolerability, and short-term efficacy of intravenous lidocaine infusions for the treatment of chronic pain in adolescents and young adults: a preliminary report. Pain Med. 2014;15(5):820–5.CrossRefPubMedGoogle Scholar
  75. 75.
    Niki Y, Kanai A, Hoshi K, Okamoto H. Immediate analgesic effect of 8% lidocaine applied to the oral mucosa in patients with trigeminal neuralgia. Pain Med. 2014;15(5):826–31.CrossRefPubMedGoogle Scholar
  76. 76.
    Wang XQ, Lv B, Wang HF, Zhang X, Yu SY, Huang XS, Zhang JT, Tian CL, Lang SY. Lamotrigine-induced severe cutaneous adverse reaction: update data from 1999–2014. J Clin Neurosci. 2015;22(6):1005–11.CrossRefPubMedGoogle Scholar
  77. 77.
    Hussami A, Fromont A, Moreau T. Recidive de nevralgies du trijumeau sous fampridine. Rev Neurol (Paris). 2015;171:A71.CrossRefGoogle Scholar
  78. 78.
    Ratté S, Prescott SA. Afferent hyperexcitability in neuropathic pain and the inconvenient truth about its degeneracy. Curr Opin Neurobiol. 2016;36:31–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Sergio Canavero
    • 1
  • Vincenzo Bonicalzi
    • 2
  1. 1.HEAVEN/GEMINI International Collaborative GroupTurinItaly
  2. 2.AOUCittà della Salute e della Scienza di Torino, Department of Neurosciences, Rita Levi MontalciniUniversità di TorinoTurinItaly

Personalised recommendations